Acquisition and Management of Data for Translational Science in Oncology

Oncology clinical trials provide opportunity to advance care for patients with cancer. Bridging basic science with bedside care, cancer clinical trials have brought new and updated scientific knowledge at a rapid pace. Managing subject data in translation science requires a sophisticated informatics infrastructure that will enable harmonized datasets across all areas that could influence outcomes. Successful translational science requires that all relevant information be made readily available in a digital format that can be queried in a facile manner. Through a translational science prism, we look at past issues in cancer clinical trials and the new National Institutes of Health/National Cancer Institute initiative to address the need of database availability at an enterprise level.

[1]  Optimisation of adaptive therapy for advanced Hodgkin lymphoma. , 2019, The Lancet. Oncology.

[2]  J. Saltz,et al.  Open access image repositories: high-quality data to enable machine learning research. , 2020, Clinical radiology.

[3]  Ashish Sharma,et al.  The public cancer radiology imaging collections of The Cancer Imaging Archive , 2017, Scientific Data.

[4]  C. N. Coleman,et al.  Imaging and Data Acquisition in Clinical Trials for Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[5]  L. Constine,et al.  Radiotherapy quality assurance report from children's oncology group AHOD0031. , 2015, International journal of radiation oncology, biology, physics.

[6]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[7]  L. Constine,et al.  Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. , 2012, International journal of radiation oncology, biology, physics.

[8]  R. Jagsi,et al.  Radiation field design in the ACOSOG Z0011 (Alliance) Trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Allen R. Chen,et al.  Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Fitzgerald.  A new model for imaging and radiation therapy quality assurance in the National Clinical Trials Network of the National Cancer Institute. , 2014, International journal of radiation oncology, biology, physics.

[11]  W. Curran,et al.  Future vision for the quality assurance of oncology clinical trials , 2013, Front. Oncol..

[12]  R. Fisher,et al.  Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Brian O'Sullivan,et al.  Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Giuliano,et al.  ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Richard Hanusik,et al.  Processes for quality improvements in radiation oncology clinical trials. , 2008, International journal of radiation oncology, biology, physics.

[16]  Breast-Cancer Therapy — Looking Back to the Future , 2007 .

[17]  Larry Norton,et al.  HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.

[18]  Fran Laurie,et al.  The Impact of Central Quality Assurance Review Prior to Radiation Therapy on Protocol Compliance: POG 9426, a Trial in Pediatric Hodgkin’s Disease. , 2005 .

[19]  T. Fitzgerald,et al.  Analysis of axillary coverage during tangential radiation therapy to the breast. , 2001, International journal of radiation oncology, biology, physics.

[20]  L. Norton,et al.  Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Behm,et al.  Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B Fisher,et al.  Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. , 1985, The New England journal of medicine.